1-6 of 6
Khalid El Ouagari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim

Gabriel Tremblay, DBA, MSc, BS, Mike Dolph, MSc BHSc, Anuja Roy, PhD, Juliette Neyra, PharmD, Khalid El Ouagari, Anna Forsythe, PharmD, MSc, MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 3410.
https://doi.org/10.1182/blood.V130.Suppl_1.3410.3410
Published: 2017
Journal Articles

Cost-Effectiveness of Ruxolitinib Versus Best-Available Therapy for Medical Treatment of Myelofibrosis: Canadian Societal Perspective

Khalid El Ouagari, PhD, Christopher John Knight, MSc, Estella T. Mendelson, BSRN, MBA
Journal: Blood
Blood (2012) 120 (21): 4255.
https://doi.org/10.1182/blood.V120.21.4255.4255
Published: 2012
Journal Articles

Cost-Effectiveness of Deferasirox (Exjade®) Versus No Chelation In Patients with Lower Risk Myelodysplastic Syndromes (MDS): A Canadian Perspective

Khalid El Ouagari, PhD, Kristen Migliaccio-Walle, BS, Helen Lau, MS, Duygu Bozkaya, MBA, MSc
Journal: Blood
Blood (2010) 116 (21): 4962.
https://doi.org/10.1182/blood.V116.21.4962.4962
Published: 2010
Journal Articles

Cost-Effectiveness of Adding Imatinib to Chemotherapy in Adult Patients with Chromosom-Positive Acute Lymphoblastic Leukemia (Ph+ALL): A Canadian Perspective

Khalid El Ouagari, PhD, Kimbach Tran, MPH, MS, Jennifer Stephens, PharmD, Marc Botteman, MSc, MA
Journal: Blood
Blood (2008) 112 (11): 2401.
https://doi.org/10.1182/blood.V112.11.2401.2401
Published: 2008
Journal Articles

Medical Costs of Adverse Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Canadian Perspective.

Nick Newton, PhD, Khalid El Ouagari, PhD, Mireille M. Goetghebeur, PhD
Journal: Blood
Blood (2007) 110 (11): 5178.
https://doi.org/10.1182/blood.V110.11.5178.5178
Published: 2007
Journal Articles

Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.

Kim Carpiuc, Khalid El Ouagari, PhD, Jennifer Stephens, Marc Botteman, WeiWei Feng, PhD, Richard C. Woodman, MD
Journal: Blood
Blood (2007) 110 (11): 4587.
https://doi.org/10.1182/blood.V110.11.4587.4587
Published: 2007